Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls

Arthritis Care and Research

Volumn 69, Issue 12, 2017, Pages 1780-1788

  Aberle, Teresa ^a   Bourn, Rebecka L ^a   Munroe, Melissa E ^a   Chen, Hua ^a   Roberts, Virginia C ^a   Guthridge, Joel M ^a   Bean, Krista ^a   Robertson, Julie M ^a   Sivils, Kathy L ^a   Rasmussen, Astrid ^a   Liles, Meghan ^a   Merrill, Joan T ^a   Harley, John B ^b   Olsen, Nancy J ^c   Karp, David R ^d   James, Judith A ^e  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; B CELL ACTIVATING FACTOR; HYDROXYCHLOROQUINE; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; CARDIOLIPIN ANTIBODY; TNFSF13B PROTEIN, HUMAN;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE SCREENING QUESTIONNAIRE; CONTROLLED STUDY; DISEASE ASSESSMENT; DISEASE CLASSIFICATION; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE; INCOMPLETE LUPUS ERYTHEMATOSUS; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; NEUROLOGIC DISEASE; PERICARDITIS; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; VERY ELDERLY; ANCESTRY GROUP; BLOOD; CASE CONTROL STUDY; CLASSIFICATION; CLINICAL TRIAL; COMPARATIVE STUDY; ETHNIC GROUP; IMMUNOLOGY; INDIRECT FLUORESCENT ANTIBODY TECHNIQUE; MIDDLE AGED; MULTICENTER STUDY; NOMENCLATURE; PREDICTIVE VALUE; PUERTO RICO; REGISTER; SEVERITY OF ILLNESS INDEX; UNITED STATES; VIRGIN ISLANDS (BRITISH); VIRGIN ISLANDS (U.S.);

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTICARDIOLIPIN; ANTIRHEUMATIC AGENTS; B-CELL ACTIVATING FACTOR; BIOMARKERS; BRITISH VIRGIN ISLANDS; CASE-CONTROL STUDIES; CONTINENTAL POPULATION GROUPS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHNIC GROUPS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PUERTO RICO; REGISTRIES; SEROLOGIC TESTS; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TERMINOLOGY AS TOPIC; UNITED STATES; UNITED STATES VIRGIN ISLANDS;

EID: 85033727500     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.23201     Document Type: Article

References (48)

1. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
2. Hochberg MC for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
3. Greer JM, Panush RS. Incomplete lupus erythematosus. Arch Int Med 1989;149:2473–6.
4. Costenbader KH, Schur PH. We need better classification and terminology for “people at high risk of or in the process of developing lupus” [editorial]. Arthritis Care Res (Hoboken) 2015;67:593–6.
5. Vila L, Mayor A, Valent A, Garc M, Vila S. Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus 2000;9:110–5.
6. Laustrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. Scand J Rheumatol 2009;38:128–32.
7. Al Daabil M, Massarotti EM, Fine A, Tsao H, Ho P, Schur PH, et al. Development of SLE among “potential SLE” patients seen in consultation: long-term follow-up. Int J Clin Pract 2014;68:1508–13.
8. Stahl Hallengren C, Nived O, Sturfelt G. Outcome of incomplete systemic lupus erythematosus after 10 years. Lupus 2004;13:85–8.
9. Deane KD, El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol 2014;10:212–28.
10. Swaak AJ, van de Brink H, Smeenk RJ, Manger K, Kalden JR, Tosi S, et al. Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford) 2001;40:89–94.
11. Olsen N, Yousif M, Mutwally A, Cory M, Elmagboul N, Karp D. Organ damage in high-risk patients with systemic and incomplete lupus syndromes. Rheumatol Int 2013;33:2585–90.
12. Chen Z, Li M-T, Xu D, Leng X-M, Wang Q, Tian X-P, et al. Organ damage in patients with incomplete lupus syndromes: from a Chinese academic center. Clin Rheumatol 2015;34:1383–9.
13. Rua-Figueroa I, Richi P, Lopez-Longo FJ, Galindo M, Calvo-Alen J, Olive-Marques A, et al. Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences. Medicine (Baltimore) 2015;94:e267.
14. Ugarte-Gil MF, Alarcón GS. Incomplete systemic lupus erythematosus: early diagnosis or overdiagnosis? Arthritis Care Res (Hoboken) 2016;68:285–7.
15. Nakken B, Bodolay E, Szodoray P. Cytokine milieu in undifferentiated connective tissue disease: a comprehensive review. Clin Rev Allergy Immunol 2015;49:152–62.
16. Heinlen LD, McClain MT, Ritterhouse LL, Bruner BF, Edgerton CC, Keith MP, et al. 60 kD Ro and nRNP A frequently initiate human lupus autoimmunity. PLoS One 2010;5:e9599.
17. Heinlen LD, Ritterhouse LL, McClain MT, Keith MP, Neas BR, Harley JB, et al. Ribosomal P autoantibodies are present before SLE onset and are directed against non-C-terminal peptides. J Mol Med (Berl) 2010;88:719–27.
18. Heinlen LD, McClain MT, Merrill J, Akbarali YW, Edgerton CC, Harley JB, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007;56:2344–51.
19. Munroe ME, Lu R, Zhao YD, Fife DA, Robertson JM, Guthridge JM, et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis 2016;75:2014–21.
20. Lu R, Munroe ME, Guthridge JM, Bean KM, Fife DA, Chen H, et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J Autoimmun 2016;74:182–93.
21. Li QZ, Zhou J, Wandstrat AE, Carr-Johnson F, Branch V, Karp DR, et al. Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin Exp Immunol 2007;147:60–70.
22. Harigai M, Kawamoto M, Hara M, Kubota T, Kamatani N, Miyasaka N. Excessive production of IFNγ in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B. J Immunol 2008;181:2211–9.
23. Li QZ, Zhou J, Lian Y, Zhang B, Branch VK, Carr-Johnson F, et al. Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes. Clin Exp Immunol 2010;159:281–91.
24. Rasmussen A, Sevier S, Kelly JA, Glenn SB, Aberle T, Cooney CM, et al. The lupus family registry and repository. Rheumatology (Oxford) 2011;50:47–59.
25. Walitt BT, Constantinescu F, Katz JD, Weinstein A, Wang H, Hernandez RK, et al. Validation of self-report of rheumatoid arthritis and systemic lupus erythematosus: The Women's Health Initiative. J Rheumatol. 2008;35(5):811–8.
26. Karlson EW, Costenbader KH, McAlindon TE, Massarotti EM, Fitzgerald LM, Jajoo R, et al. High sensitivity, specificity and predictive value of the Connective Tissue Disease Screening Questionnaire among urban African-American women. Lupus 2005;14:832–6.
27. Petri M, Orbai A-M, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677–86.
28. McClain MT, Arbuckle MR, Heinlen LD, Dennis GJ, Roebuck J, Rubertone MV, et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004;50:1226–32.
29. Bruner BF, Guthridge JM, Lu R, Vidal G, Kelly JA, Robertson JM, et al. Comparison of autoantibody specificities between traditional and bead-based assays in a large, diverse collection of patients with systemic lupus erythematosus and family members. Arthritis Rheum 2012;64:3677–86.
30. Lu R, Robertson JM, Bruner BF, Guthridge JM, Neas BR, Nath SK, et al. Multiple autoantibodies display association with lymphopenia, proteinuria, and cellular casts in a large, ethnically diverse SLE patient cohort. Autoimmune Dis 2012;2012:819634.
31. Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Pediatr 2007;96:644–7.
32. Bello GA, Brown MA, Kelly JA, Thanou A, James JA, Montgomery CG. Development and validation of a simple lupus severity index using ACR criteria for classification of SLE. Lupus Sci Med 2016;3:e000136.
33. Ziakas PD, Dafni UG, Giannouli S, Tzioufas AG, Voulgarelis M. Thrombocytopaenia in lupus as a marker of adverse outcome: seeking Ariadne's thread. Rheumatology (Oxford) 2006;45:1261–5.
34. Fernández M, Alarcón GS, Apte M, Andrade RM, Vilá LM, Reveille JD, et al. Systemic lupus erythematosus in a multiethnic US cohort: XLIII. The significance of thrombocytopenia as a prognostic factor. Arthritis Rheum 2007;56:614–21.
35. Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009;119:1066–73.
36. Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken) 2015;67:891–7.
37. Virdis A, Tani C, Duranti E, Vagnani S, Carli L, Kuhl AA, et al. Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. Arthritis Res Ther 2015;17:277.
38. Fessler BJ, Alarcón GS, McGwin G Jr, Roseman J, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473–80.
39. Pons-Estel GJ, Alarcón GS, McGwin G Jr, Danila MI, Zhang J, Bastian HM, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 2009;61:830–9.
40. James J, Kim-Howard X, Bruner B, Jonsson M, McClain M, Arbuckle M, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007;16:401–9.
41. Meinao IM, Sato EI, Andrade LE, Ferraz MB, Atra E. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 1996;5:237–41.
42. Kan H, Nagar S, Patel J, Wallace DJ, Molta C, Chang DJ. Longitudinal treatment patterns and associated outcomes in patients with newly diagnosed systemic lupus erythematosus. Clin Ther 2016;38:610–24.
43. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20–8.
44. Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol 2011;7:718–29.
45. Inês L, Silva C, Galindo M, López-Longo FJ, Terroso G, Romao VC, et al. Classification of systemic lupus erythematosus: Systemic Lupus International Collaborating Clinics versus American College of Rheumatology criteria. A comparative study of 2,055 patients from a real-life, international systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) 2015;67:1180–5.
46. Pons-Estel GJ, Wojdyla D, McGwin G Jr, Magder LS, Petri MA, Pons-Estel BA, et al. The American College of Rheumatology and the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus in two multiethnic cohorts: a commentary. Lupus 2014;23:3–9.
47. Aberle T, Bourn RL, Chen H, Roberts VC, Guthridge JM, Bean KM, et al. Use of SLICC criteria in a large, diverse lupus registry enables SLE classification of a subset of ACR-designated ILE subjects. Lupus Sci Med 2017;4:e000176.
48. Slight-Webb S, Lu R, Ritterhouse LL, Munroe ME, Maecker HT, Fathman CG, et al. Autoantibody-positive healthy individuals display unique immune profiles that may regulate autoimmunity. Arthritis Rheumatol 2016;68:2492–502.